Nkarta develops engineered natural killer cell therapies for autoimmune diseases, led by its candidate NKX019. It last closed at $1.14 on Nov 20, up 1.34% on the day. The next earnings report for NKTX is expected around Wed, Mar 24, 2027, after the close. Over its last 8 reports the stock moved an average of 11.2% the session after earnings. Over the last 12 months NKTX insiders bought $0 of stock on the open market and sold $70K, according to SEC Form 4 filings.
AI Auto Pilots
Is NKTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NKTX.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on NKTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
NKTX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 29% below its 20 day and 78% below its 50 day average. It is 118% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the swing low (Nov 9) at $1.13, and the nearest resistance the Pivot at $1.15.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 14.8%/day
Key levels
$3.7252 week high+226.3%
$2.47200 day average+116.7%
$2.32100 day average+103.5%
$2.0250 day average+77.2%
$1.84Swing high (Nov 6)+61.4%
$1.4620 day average+28.1%
$1.20Pivot R1+5.3%
$1.15Pivot+0.9%
$1.14Last close
$1.13Swing low (Nov 9)−0.9%
$1.1052 week low−3.5%
$1.09Pivot S1−4.4%
Indicators
RSI (14)
30.63
Weak, oversold below 30
Neutral
MACD
-0.24
Below its signal line
Bearish
Stochastic
4.1
Near the bottom of its range
Oversold
ADX (14)
48.5
Strong downtrend
Williams %R
-95.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-108.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−34.4%
Change over 10 sessions
Bearish
ATR (14)
$0.17
Typical daily range, 14.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 35.8%/day
Key levels
$3.7252 week high+226.3%
$2.47200 day average+116.7%
$2.32100 day average+103.5%
$2.0250 day average+77.2%
$1.84Swing high (Nov 6)+61.4%
$1.4620 day average+28.1%
$1.20Pivot R1+5.3%
$1.15Pivot+0.9%
$1.14Last close
$1.13Swing low (Nov 9)−0.9%
$1.1052 week low−3.5%
$1.09Pivot S1−4.4%
Indicators
RSI (14)
31.76
Weak, oversold below 30
Neutral
MACD
-0.31
Below its signal line
Bearish
Stochastic
6.3
Near the bottom of its range
Oversold
ADX (14)
20.4
Weak trend
Williams %R
-98.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-168.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−61.0%
Change over 10 sessions
Bearish
ATR (14)
$0.41
Typical daily range, 35.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NKTX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NKTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow NKTX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for NKTXHow many large options trades hit NKTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in NKTX in the last 90 days.
From SEC Form 4 filings by NKTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NKTX is in one of them and how their past NKTX trades turned out.
Nkarta is a clinical stage biopharmaceutical company based in South San Francisco, California. It develops engineered natural killer cell therapies made from cells donated by healthy people and produced in advance, so they can be given to patients without waiting for a custom batch. Its lead product candidate, NKX019, targets CD19 and is being studied in autoimmune diseases such as lupus nephritis and systemic sclerosis. The company aims its therapies at people living with these conditions.